Yes - short-term GLP-1 use can be effective, but only when it is part of a broader plan
Eight studies had low risk of bias (43, 5557, 61, 64, 71, 72), 11 studies had moderate risk of bias (44, 48, 50, 54, 58, 63, 65, 68, 74, 75, 79) and 22 studies had high risk of bias (16, 17, 23, 4547, 49, 5153, 59, 60, 62, 66, 67, 69, 70, 73, 7678, 80)
Peptides are not steroids
In fact, research published in Diabetes, Obesity, and Metabolism found that participants regained two-thirds of the weight they had previously lost after they stopped using Wegovy
Retatrutide is a triple-receptor agonist, meaning it simultaneously activates three distinct hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor